{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:29:56Z","timestamp":1783747796733,"version":"3.55.0"},"reference-count":56,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jbcpp-2020-0115_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Ciprofloxacin (CIPRO) is a fluroquinolone class antibiotic used commonly for the treatment of various acute and chronic bacterial infections. However, recently there is increase in the case reports of CIPRO-induced Cutaneous Adverse Drug Reactions (CADRs). We aim to systematically review all the descriptive studies of CIPRO induced CADRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2020-0115_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medline (via PubMed) was searched without any language or date restriction from inception to March 2019 using search terms of \u201cCiprofloxacin\u201d and \u201cCutaneous reactions.\u201d We included only the descriptive studies, which elucidate the CADRs experienced by the patients following the administration of CIPRO. Two reviewers involved in study selection, data extraction and quality assessment of the included studies. Discrepancies were resolved by consensus between the reviewers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2020-0115_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-nine studies (out of 446) were found to be eligible for the final inclusion. The dose of CIPRO among the included studies was ranging from 500 to 1,000\u00a0mg\/day and duration of treatment was between 7 and 10\u00a0days. The most common CADRs observed were toxic epidermal necrolysis, Stevens\u2013Johnson syndrome, fixed drug eruptions, bullous fixed drug reaction, acute generalized pustulosis, erythema multiforme, drug rash with eosinophilia and systemic symptoms and erythema nodosum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2020-0115_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Management of the CIPRO-induced CADRs is recommended with the complete cessation of the CIPRO, followed by supportive management with oral or topical glucocorticoids, emollients, and topical moisturizers. CIPRO is likely to cause CADRs, physicians should be vigilant while prescribing it to the patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jbcpp-2020-0115","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T17:32:17Z","timestamp":1615915937000},"page":"327-346","source":"Crossref","is-referenced-by-count":13,"title":["Ciprofloxacin-induced cutaneous adverse drug events: a systematic review of descriptive studies"],"prefix":"10.1515","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0611-4191","authenticated-orcid":false,"given":"Ananth","family":"Kashyap","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice , Sarada Vilas College of Pharmacy , Mysuru , Karnataka , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahana","family":"Sreenivasan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice , M S Ramaiah University of Applied Sciences , Bangalore , Karnataka , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8523-7968","authenticated-orcid":false,"given":"Asha K","family":"Rajan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice , Jaya College of Pharmacy , Thiruninravur , Chennai , Tamil Nadu , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-7764","authenticated-orcid":false,"given":"Muhammed","family":"Rashid","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice , Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University BG Nagara , Nagamangala, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8924-8242","authenticated-orcid":false,"given":"Manik","family":"Chhabra","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice , Indo Soviet Friendship College of Pharmacy , Moga , Punjab , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_001","unstructured":"Thai, T, Zito, PM. Ciprofloxacin. Treasure Island (FL): Stat Pearls NCBI Book Resource; 2019."},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_002","doi-asserted-by":"crossref","unstructured":"Campoli Richards, DM, Monk, JP, Price, A, Benfield, P, Todd, PA, Ward, A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1988;35:373\u2013447. https:\/\/doi.org\/10.2165\/00003495-198835040-00003.","DOI":"10.2165\/00003495-198835040-00003"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_003","doi-asserted-by":"crossref","unstructured":"Fish, DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001;21:253S\u201372S. https:\/\/doi.org\/10.1592\/phco.21.16.253s.33993.","DOI":"10.1592\/phco.21.16.253S.33993"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_004","unstructured":"FDA label of ciprofloxacin [Online]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/019537s082,020780s040lbl.pdf [Accessed Dec 2019]."},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_005","doi-asserted-by":"crossref","unstructured":"Jeevanagi, SR, Manjunath, S, Wali, VK. A case of ciprofloxacin induced erythema multiforme. Indian J Pharmacol 2008;40:45\u20136. https:\/\/doi.org\/10.4103\/0253-7613.40490.","DOI":"10.4103\/0253-7613.40490"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_006","doi-asserted-by":"crossref","unstructured":"Bohm, R, Cascorbi, I. Pharmacogenetics and predictive testing of drug hypersensitivity reactions. Front Pharmacol 2016;7:1\u201311. https:\/\/doi.org\/10.3389\/fphar.2016.00396.","DOI":"10.3389\/fphar.2016.00396"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_007","doi-asserted-by":"crossref","unstructured":"Rashid, M, Kashyap, A, Undela, K. Valproic acid and Stevens\u2013Johnson syndrome: a systematic review of descriptive studies. Int J Dermatol 2019;58:1014\u201322. https:\/\/doi.org\/10.1111\/ijd.14411.","DOI":"10.1111\/ijd.14411"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_008","doi-asserted-by":"crossref","unstructured":"Rashid, M, Rajan, AK, Chhabra, M, Kashyap, A. Levetiracetam and cutaneous adverse reactions: a systematic review of descriptive studies. Seizure 2020;75:101\u20139. https:\/\/doi.org\/10.1016\/j.seizure.2020.01.002.","DOI":"10.1016\/j.seizure.2020.01.002"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_009","unstructured":"Howick, J, Chalmers, I, Glasziou, P. The Oxford 2011 levels of evidence. Oxford, UK: Oxford Centre for Evidence-Based Medicine; 2011."},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_010","doi-asserted-by":"crossref","unstructured":"Murad, MH, Sultan, S, Haffar, S, Bazerbachi, F. Methodological quality and synthesis of case series and case reports. BMJ Evidence-Based Med 2018;23:60\u20133. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853.","DOI":"10.1136\/bmjebm-2017-110853"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_011","doi-asserted-by":"crossref","unstructured":"Mollica, AJ, Grant, E, Malik, A, Claydon, M. Ciprofloxacin-induced bullae of the lower extremity: a case of a fixed drug reaction. J Am Podiatr Med Assoc 2019;109:155\u20138. https:\/\/doi.org\/10.7547\/17-088.","DOI":"10.7547\/17-088"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_012","doi-asserted-by":"crossref","unstructured":"Cravens, MG, Sherman, N, Sawaya, J. Ciprofloxacin-induced Stevens\u2013Johnson syndrome with grapefruit juice consumption: a case report. Cureus 2019;11:1\u20134. https:\/\/doi.org\/10.7759\/cureus.3827.","DOI":"10.7759\/cureus.3827"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_013","doi-asserted-by":"crossref","unstructured":"Iliyas, M, Reddy, MR, Devi, U. Ciprofloxacin-induced generalised non-bullous fixed drug eruption. BMJ Case Rep 2018;4:1\u20134.","DOI":"10.1136\/bcr-2018-224858"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_014","doi-asserted-by":"crossref","unstructured":"Arnold, M, Wilkerson, M. A case of erythema multiforme major following administration of ciprofloxacin ophthalmic drops. Dermatol Online J 2017;23:1\u20132.","DOI":"10.5070\/D32310036998"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_015","doi-asserted-by":"crossref","unstructured":"Tajmir-Riahi, A, W\u00f6rl, P, Harrer, T, Schliep, S, Schuler, G, Simon, M. Life-threatening atypical case of acute generalized exanthematous pustulosis. Int Arch Allergy Immunol 2017;174:108\u201311. https:\/\/doi.org\/10.1159\/000480700.","DOI":"10.1159\/000480700"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_016","doi-asserted-by":"crossref","unstructured":"GarnicaVelandia, DR, Dalmau Duch, G, G\u00e1zquez Garc\u00eda, V, Indiveri, M, GaigJan\u00e9, P. Fixed drug eruption induced by ciprofloxacin and cross\u2010reactivity to other quinolones. Contact Dermatitis 2017;77:261\u20132. https:\/\/doi.org\/10.1111\/cod.12813.","DOI":"10.1111\/cod.12813"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_017","doi-asserted-by":"crossref","unstructured":"Pannu, AK, Adarsh, MB, Sharma, N. Not all febrile critical illness with rash is infective: drug reaction may be a mimic. Indian journal of critical care medicine: peer-reviewed. Indian J Crit Care Med 2017;21:229. https:\/\/doi.org\/10.4103\/ijccm.ijccm_397_16.","DOI":"10.4103\/ijccm.IJCCM_397_16"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_018","doi-asserted-by":"crossref","unstructured":"Foti, C, Romita, P, Zanframundo, G, Mastrolonardo, M, Angelini, G, Calogiuri, G, et al.. Ciprofloxacin induced acute generallisedexanthematous pustulosis. Indian J Pharmacol 2017;49:119. https:\/\/doi.org\/10.4103\/0253-7613.201014.","DOI":"10.4103\/0253-7613.201014"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_019","doi-asserted-by":"crossref","unstructured":"Nair, PA. Ciprofloxacin induced bullous fixed drug reaction: three case reports. J Fam Med Prim Care 2015;4:269. https:\/\/doi.org\/10.4103\/2249-4863.154673.","DOI":"10.4103\/2249-4863.154673"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_020","unstructured":"Pal, A, Sen, S, Das, S, Biswas, A, Tripathi, SK. A case of self-treatment induced recurrent fixed drug eruptions associated with the use of different fixed dose combinations of fluoroquinolone-nitroimidazole. Iran J Med Sci 2014;39:584."},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_021","doi-asserted-by":"crossref","unstructured":"Moghaddam, S, Connolly, D. Photo induced Stevens\u2013Johnson syndrome. J Am Acad Dermatol 2014;71:e82\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2014.02.033.","DOI":"10.1016\/j.jaad.2014.02.033"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_022","doi-asserted-by":"crossref","unstructured":"Alkhateeb, H, Said, S, Cooper, CJ, Gaur, S, Porres-Aguilar, M. DRESS syndrome following ciprofloxacin exposure: an unusual association. Am J Case Rep 2013;14:526. https:\/\/doi.org\/10.12659\/ajcr.889703.","DOI":"10.12659\/AJCR.889703"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_023","doi-asserted-by":"crossref","unstructured":"Jain, SP, Jain, PA. Bullous fixed drug eruption to ciprofloxacin: a case report. J Clin Diagn Res 2013;7:744. https:\/\/doi.org\/10.7860\/JCDR\/2013\/4757.2901.","DOI":"10.7860\/JCDR\/2013\/4757.2901"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_024","doi-asserted-by":"crossref","unstructured":"Shilpashree, HS, Sarapur, S. Ciprofloxacin-induced erythema multiforme. J Pharmacol Pharmacother 2012;3:339. https:\/\/doi.org\/10.4103\/0976-500x.103696.","DOI":"10.4103\/0976-500X.103696"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_025","unstructured":"Artukovi\u0107, M, Ku\u0161telega, J, Lugovi\u0107-Mihi\u0107, L. DRESS syndrome with mild manifestations as a diagnostic and therapeutic problem: case report. Acta Clin Croat 2010;49:479\u201384."},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_026","doi-asserted-by":"crossref","unstructured":"Gheith, O, Al\u2010Otaibi, T, Tawab, KA, Said, T, Balaha, MA, Halim, MA, et al.. Erythema nodosum in renal transplant recipients: multiple cases and review of literature. Transpl Infect Dis 2010;12:164\u20138. https:\/\/doi.org\/10.1111\/j.1399-3062.2009.00474.x.","DOI":"10.1111\/j.1399-3062.2009.00474.x"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_027","doi-asserted-by":"crossref","unstructured":"Cholongitas, E, Georgousaki, C, Spyrou, S, Katsogridakis, K, Dasenaki, M. Stevens\u2013Johnson syndrome related to ciprofloxacin, possibly enhanced by overadministration of levothyroxine. Dermatol Online J 2009;15:1\u20134.","DOI":"10.5070\/D31192764X"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_028","doi-asserted-by":"crossref","unstructured":"Upadya, G, Ruxana, K. Toxic epidermal necrolysis and agranulocytosis: rare adverse effects of ciprofloxacin. Indian J Med Sci 2009;63:461. https:\/\/doi.org\/10.4103\/0019-5359.57648.","DOI":"10.4103\/0019-5359.57648"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_029","doi-asserted-by":"crossref","unstructured":"Lagoudianakis, E, Pappas, A, Koronakis, N, Dallianoudis, I, Kotzadimitriou, K, Chrysikos, J, et al.. Recurrent erythema multiforme after alcohol ingestion in a patient receiving ciprofloxacin: a case report. Cases J 2009;2:7787. https:\/\/doi.org\/10.4076\/1757-1626-2-7787.","DOI":"10.4076\/1757-1626-2-7787"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_030","doi-asserted-by":"crossref","unstructured":"Maunz, G, Conzett, T, Zimmerli, W. Cutaneous vasculitis associated with fluoroquinolones. Infection 2009;37:466. https:\/\/doi.org\/10.1007\/s15010-009-8437-4.","DOI":"10.1007\/s15010-009-8437-4"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_031","doi-asserted-by":"crossref","unstructured":"Okan, G, Yaylaci, S, Peker, O, Kaymakoglu, S, Saruc, M. Vanishing bile duct and Stevens\u2013Johnson syndrome associated with ciprofloxacin treated with tacrolimus. World J Gastroenterol 2008;14:4697. https:\/\/doi.org\/10.3748\/wjg.14.4697.","DOI":"10.3748\/wjg.14.4697"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_032","doi-asserted-by":"crossref","unstructured":"Kayabas, U, Yetkin, F, Firat, AK, Ozcan, H, Bayindir, Y. Ciprofloxacin-induced urticaria and tenosynovitis: a case report. Chemotherapy 2008;54:288\u201390. https:\/\/doi.org\/10.1159\/000149720.","DOI":"10.1159\/000149720"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_033","doi-asserted-by":"crossref","unstructured":"Degiovanni, CV, Darley, CR. Pseudoporphyria occurring during a course of ciprofloxacin. Clin Exp Dermatol 2008;33:109. https:\/\/doi.org\/10.1111\/j.1365-2230.2007.02597.x.","DOI":"10.1111\/j.1365-2230.2007.02597.x"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_034","doi-asserted-by":"crossref","unstructured":"H\u00e4usermann, P, Scherer, K, Weber, M, Bircher, AJ. Ciprofloxacin-induced acute generalized exanthematous pustulosis mimicking bullous drug eruption confirmed by a positive patch test. Dermatology 2005;211:277\u201380. https:\/\/doi.org\/10.1159\/000087024.","DOI":"10.1159\/000087024"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_035","doi-asserted-by":"crossref","unstructured":"Mandal, B, Steward, M, Singh, S, Jones, H. Ciprofloxacin-induced toxic epidermal necrolysis (TEN) in a nonagerian: a case report. Age Ageing 2004;33:405\u20136. https:\/\/doi.org\/10.1093\/ageing\/afh088.","DOI":"10.1093\/ageing\/afh088"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_036","doi-asserted-by":"crossref","unstructured":"Jongen-Lavrencic, M, Schneeberger, PM, Van Der Hoeven, JG. Ciprofloxacin-induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus. Infection 2003;31:428\u20139. https:\/\/doi.org\/10.1007\/s15010-003-2128-3.","DOI":"10.1007\/s15010-003-2128-3"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_037","doi-asserted-by":"crossref","unstructured":"H\u00e4llgren, J, Tengvall-Linder, M, Persson, M, Wahlgren, CF. Stevens\u2013Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug. J Am Acad Dermatol 2003;49:267\u20139. https:\/\/doi.org\/10.1016\/s0190-9622(03)00478-x.","DOI":"10.1016\/S0190-9622(03)00478-X"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_038","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez\u2010Morales, A, Llamazares, AA, Benito, RP, Cocera, CM. Fixed drug eruption from quinolones with a positive lesional patch test to ciprofloxacin. Contact Dermatitis 2001;44:246\u201363.","DOI":"10.1034\/j.1600-0536.2001.440409-10.x"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_039","doi-asserted-by":"crossref","unstructured":"Jaff\u00e9, A, Bush, A. If you can\u2019t stand the rash, get out of the kitchen: an unusual adverse reaction to ciprofloxacin. Pediatr Pulmonol 1999;28:449\u201350.","DOI":"10.1002\/(SICI)1099-0496(199912)28:6<449::AID-PPUL11>3.3.CO;2-8"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_040","doi-asserted-by":"crossref","unstructured":"Vaidyanathan, S, Singh, G, Sett, P, Watt, JW, Soni, BM, Oo, T. Cutaneous adverse reaction to ciprofloxacin precipitated by ingestion of alcohol in a tetraplegic patient. Spinal Cord 1999;37:663. https:\/\/doi.org\/10.1038\/sj.sc.3100896.","DOI":"10.1038\/sj.sc.3100896"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_041","doi-asserted-by":"crossref","unstructured":"Bircher, AJ, Rutishauser, M. Oral \u201cdesensitization\u201d of maculopapular exanthema from ciprofloxacin. Allergy 1997;52:1246\u20138. https:\/\/doi.org\/10.1111\/j.1398-9995.1997.tb02534.x.","DOI":"10.1111\/j.1398-9995.1997.tb02534.x"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_042","doi-asserted-by":"crossref","unstructured":"Livasy, CA, Kaplan, AM. Ciprofloxacin induced toxic epidermal necrolysis: a case report. Dermatology 1997;195:173\u201317. https:\/\/doi.org\/10.1159\/000245726.","DOI":"10.1159\/000245726"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_043","doi-asserted-by":"crossref","unstructured":"Yerasi, AB, Oertel, MD. Ciprofloxacin induced toxic epidermal necrolysis. Ann Pharmacother 1996;30:297. https:\/\/doi.org\/10.1177\/106002809603000317.","DOI":"10.1177\/106002809603000317"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_044","doi-asserted-by":"crossref","unstructured":"Ayllon, ML, Martinez, MG, Mosquera, MR, Laguna Martinez, JJ, Martiartu, MO, Fernandez de Miguel, C. Fixed eruption caused by ciprofloxacin without cross\u2010sensitivity to norfloxacin. Allergy 1995;50:598\u20139. https:\/\/doi.org\/10.1111\/j.1398-9995.1995.tb01206.x.","DOI":"10.1111\/j.1398-9995.1995.tb01206.x"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_045","doi-asserted-by":"crossref","unstructured":"Annapureddy, RR, Navyasree, T, Challa, SR, Raja Shree, G, Pavani, AL. Ciprofloxacin induced Stevens\u2013Johnson syndrome. J Clin Diagn Res 2018;12:1\u20132.","DOI":"10.7860\/JCDR\/2018\/32032.11063"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_046","doi-asserted-by":"crossref","unstructured":"Kawada, A, Hiruma, M, Morimoto, K, Ishibashi, A, Banba, H. Fixed drug eruption induced by ciprofloxacin followed by ofloxacin. Contact Dermatitis 1994;31:182\u20133. https:\/\/doi.org\/10.1111\/j.1600-0536.1994.tb01962.x.","DOI":"10.1111\/j.1600-0536.1994.tb01962.x"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_047","doi-asserted-by":"crossref","unstructured":"Win, A, Evers, ML, Chmel, H. Stevens\u2013Johnson syndrome presumably induced by ciprofloxacin. Int J Dermatol 1994;33:512\u20134. https:\/\/doi.org\/10.1111\/j.1365-4362.1994.tb02870.x.","DOI":"10.1111\/j.1365-4362.1994.tb02870.x"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_048","doi-asserted-by":"crossref","unstructured":"Moshfeghi, M, Mandler, HD. Ciprofloxacin-induced toxic epidermal necrolysis. Ann Pharmacother 1993;27:1467\u20139. https:\/\/doi.org\/10.1177\/106002809302701212.","DOI":"10.1177\/106002809302701212"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_049","doi-asserted-by":"crossref","unstructured":"Tham, TK, Allen, G, Hayes, D, Mcgrady, B, Riddell, J. Possible association between toxic epidermal necrolysis and ciprofloxacin. Lancet 1991;338:522. https:\/\/doi.org\/10.1016\/0140-6736(91)90602-l.","DOI":"10.1016\/0140-6736(91)90602-L"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_050","unstructured":"Mamatha, K, Ravali, TR, Chiranjeevi, P, Maheshwari, EA. A case report on ciprofloxacin induced erythema multiforme. MSRUAS-SAS Tech J 2015;14:45\u20138."},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_051","doi-asserted-by":"crossref","unstructured":"McNeil, BD, Pundir, P, Meeker, S, Han, L, Undem, BJ, Kulka, M, et al.. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 2015;519:237\u201341. https:\/\/doi.org\/10.1038\/nature14022.","DOI":"10.1038\/nature14022"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_052","doi-asserted-by":"crossref","unstructured":"McGee, EU, Samuel, E, Boronea, B, Dillard, N, Milby, MN, Lewis, SJ. Quinolone allergy. Pharmacy 2019;7:97. PMID: 31330937; PMCID: PMC6789783. https:\/\/doi.org\/10.3390\/pharmacy7030097.","DOI":"10.3390\/pharmacy7030097"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_053","doi-asserted-by":"crossref","unstructured":"Demir, S, Gelincik, A, Akdeniz, N, Aktas-Cetin, E, Olgac, M, Unal, D, et al.. Usefulness of in\u00a0vivo and in\u00a0vitro diagnostic tests in the diagnosis of hypersensitivity reactions to quinolones and in the evaluation of cross-reactivity: a comprehensive study including the latest quinolone gemifloxacin. Allergy Asthma Immunol Res 2017;9:347\u201359. https:\/\/doi.org\/10.4168\/aair.2017.9.4.347.","DOI":"10.4168\/aair.2017.9.4.347"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_054","unstructured":"Venturini D\u00edaz, M, Lobera Labairu, T, del Pozo Gil, MD, Blasco Sarrami\u00e1n, A, Gonz\u00e1lez Mahave, I. In vivo diagnostic tests in adverse reactions to quinolones. J Investig Allergol Clin Immunol 2007;17:393\u20138."},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_055","doi-asserted-by":"crossref","unstructured":"Bro\u017e, P, Harr, TH, Hecking, C, Grize, L, Scherer, K, Jaeger, KA, et al.. Nonirritant intradermal skin test concentrations of ciprofloxacin, clarithromycin, and rifampicin. Allergy 2012;67:647\u201352.","DOI":"10.1111\/j.1398-9995.2012.02807.x"},{"key":"2025121209185721574_j_jbcpp-2020-0115_ref_056","doi-asserted-by":"crossref","unstructured":"Rueff, F, Bergmann, KC, Brockow, K, Fuchs, T, Gr\u00fcbl, A, Jung, K, et al.. Skin tests for diagnostics of allergic immediate-type reactions. Guideline of the German Society for Allergology and Clinical Immunology. Pneumologie 2011;65:484. https:\/\/doi.org\/10.1055\/s-0030-1256476.","DOI":"10.1055\/s-0030-1256476"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2020-0115\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2020-0115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:06:05Z","timestamp":1765541165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2020-0115\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":56,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,29]]},"published-print":{"date-parts":[[2022,5,23]]}},"alternative-id":["10.1515\/jbcpp-2020-0115"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2020-0115","relation":{},"ISSN":["2191-0286"],"issn-type":[{"value":"2191-0286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,16]]}}}